CTOs on the Move

WeedMD

www.weedmd.com

 
WeedMD Inc. is the publicly-traded parent company of WeedMD RX Inc. and Starseed Medicinal Inc., federally-licensed producers of cannabis products for both the medical and adult-use markets. The Company owns and operates a 158-acre state-of-the-art greenhouse, outdoor and processing facility located in Strathroy, Ontario as well as CX Industries Inc., a wholly-owned subsidiary which specializes in cannabis extraction from the Company`s fully-licensed 26,000 sq. ft. Aylmer, Ontario processing facility. With the addition of Starseed, a medical-centric operator based in Bowmanville, Ontario, WeedMD has expanded its multi-channeled distribution strategy. Starseed`s industry-first, exclusive partnership with LiUNA, the largest construction union in Canada, ...
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million
  • www.weedmd.com
  • 250 Elm Street
    Aylmer, ON CAN N5H 2M8
  • Phone: 844.933.3636

Executives

Name Title Contact Details

Similar Companies

Petvisor

Petvisor is a company that delivers a suite of mobile-enabled technologies to pet care professionals, helping them care for pet families. They provide tools to engage customers, streamline operations, and grow businesses in the veterinary health and pe...

CCBR-SYNARC

Synarc enables its clients to demonstrate the efficacy of new therapies across a broad range of therapeutic areas through highly specialized medical imaging and molecular marker techniques.

Modern Concepts Medical

Modern Concepts Medical is a Montebello, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CALSTAR, California Shock Trauma Air Rescue

CALSTAR, California Shock Trauma Air Rescue is a Mcclellan, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Envisia Therapeutics

Envisia Therapeutics, formed by Liquidia Technologies in 2013, is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® platform to develop therapies for a variety of ocular conditions, the most advanced of which is ENV515, for the treatment of glaucoma. ENV515 is a novel extended-release formulation of a prostaglandin analogue formulation. It has the potential to significantly limit disease progression and vision loss through improved product performance and patient compliance. Envisia is located in Research Triangle Park, North Carolina.